Filing Details
- Accession Number:
- 0001209191-16-150960
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-11-17 17:41:00
- Reporting Period:
- 2016-11-15
- Filing Date:
- 2016-11-17
- Accepted Time:
- 2016-11-17 17:41:00
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1396814 | Pacira Pharmaceuticals Inc. | PCRX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1383242 | S James Scibetta | C/O Pacira Pharmaceuticals, Inc. 5 Sylvan Way, Suite 300 Parsippany NJ 07054 | President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-11-15 | 20,000 | $1.61 | 47,084 | No | 4 | M | Direct | |
Common Stock | Disposition | 2016-11-15 | 20,000 | $36.50 | 27,084 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2016-11-15 | 20,000 | $0.00 | 20,000 | $1.61 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
2,373 | 2020-09-02 | No | 4 | M | Direct |
Footnotes
- The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- The option vested as to 50% of the options on September 2, 2010 and vests as to the remaining options in successive equal monthly installments for the subsequent 24 months. The options become exercisable, to the extent vested, from and after the issuer's initial public offering.